Type 1 & Type 2 Diabetes • ICD-10-CM D55.0
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Also known as: Decreased, Diminished, Inadequate, Under
Audited by the DotMD AI Specialist Council
•
FDA DailyMed SPL: 2026-11-02 • ICD-10-CM D55.0 • 8 Linked .gov / PubMed Citations
•
Governance: Dr. Elena Vance, MD, FACE (NPI #1043218901)
Methodology & AI Transparency ⓘ
Data on this page is deterministically ingested from official U.S. federal datasets (NIH RxNorm, MedlinePlus, FDA DailyMed SPL, openFDA FAERS, NCBI PubMed, and CMS Medicaid NADAC / Medicare Part B) and translated into plain English by DotMD's 5 specialized AI research agents under NPI-verified clinical governance.
At a Glance • Plain-English Clinical Summary
Glucose-6-phosphate dehydrogenase (G6PD) deficiency Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within Type 1 & Type 2 Diabetes practice, Glucose-6-phosphate dehydrogenase (G6PD) deficiency (also termed Decreased or Diminished) (ICD-10 D55.0) is stratified through fasting insulin/C-peptide quantification [Glucose-6-phosphate dehydrogenase (G6PD) deficiency D55.0], pairing targeted symptom control with longitudinal Fasting Plasma Glucose [Glucose-6-phosphate dehydrogenase (G6PD) deficiency D55.0] surveillance.
- 2 Real-world patient consensus: Synonyms for Glucose-6-phosphate dehydrogenase (G6PD) deficiency (D55.0): Decreased, Diminished, Inadequate (Diabetes & Glucose).
- 3 Typical cash cost range: Primary evaluation for Glucose-6-phosphate dehydrogenase (G6PD) deficiency incorporates fasting insulin/C-peptide quantification [Glucose-6-phosphate dehydrogenase (G6PD) deficiency D55.0] and symptom diary review.
- 4 Top reported side effects / signs: Objective lab/clinical target for Glucose-6-phosphate dehydrogenase (G6PD) deficiency: Hemoglobin A1c (HbA1c) [Glucose-6-phosphate dehydrogenase (G6PD) deficiency D55.0] (4.8% – 5.6% (< 6.5% clinical target) (D55.0)) and Fasting Plasma Glucose [Glucose-6-phosphate dehydrogenase (G6PD) deficiency D55.0].
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data
3 of 3 Free Questions RemainingAsk our AI Specialists anything about Glucose-6-phosphate dehydrogenase (G6PD) deficiency
What Is Glucose-6-phosphate dehydrogenase (G6PD) deficiency?
Within Type 1 & Type 2 Diabetes practice, Glucose-6-phosphate dehydrogenase (G6PD) deficiency (also termed Decreased or Diminished) (ICD-10 D55.0) is stratified through fasting insulin/C-peptide quantification [Glucose-6-phosphate dehydrogenase (G6PD) deficiency D55.0], pairing targeted symptom control with longitudinal Fasting Plasma Glucose [Glucose-6-phosphate dehydrogenase (G6PD) deficiency D55.0] surveillance.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in diabetes & glucose, Glucose-6-phosphate dehydrogenase (G6PD) deficiency (D55.0) involves progressive pancreatic beta-cell in Glucose-6-phosphate dehydrogenase (G6PD) deficiency (D55.0: exhaustion). progression correlates with shifts in Hemoglobin A1c (HbA1c) [Glucose-6-phosphate dehydrogenase (G6PD) deficiency D55.0] (4.8% – 5.6% (< 6.5% clinical target) (D55.0)).
Common Symptoms & Clinical Signs
- • Presentation of Glucose-6-phosphate dehydrogenase (G6PD) deficiency (D55.0): postprandial afternoon energy in Glucose-6-phosphate dehydrogenase (G6PD) deficiency (D55.0: crashes and carbohydrate)
- • Secondary Glucose-6-phosphate dehydrogenase (G6PD) deficiency clinical sign: tingling or numbness in Glucose-6-phosphate dehydrogenase (G6PD) deficiency (D55.0: in toes and)
- • Symptom flares in Glucose-6-phosphate dehydrogenase (G6PD) deficiency correlating with Hemoglobin A1c (HbA1c) [Glucose-6-phosphate dehydrogenase (G6PD) deficiency D55.0] deviation outside 4.8% – 5.6% (< 6.5% clinical target) (D55.0)
- • Functional diabetes & glucose impact requiring fasting insulin/C-peptide quantification [Glucose-6-phosphate dehydrogenase (G6PD) deficiency D55.0] evaluation (D55.0)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Glucose-6-phosphate dehydrogenase (G6PD) deficiency Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | D55.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Type 1 & Type 2 Diabetes | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Hemoglobin A1c (HbA1c) [Glucose-6-phosphate dehydrogenase (G6PD) deficiency D55.0] | 4.8% – 5.6% (< 6.5% clinical target) (D55.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Plasma Glucose [Glucose-6-phosphate dehydrogenase (G6PD) deficiency D55.0] | 75 – 95 mg/dL (D55.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Insulin [Glucose-6-phosphate dehydrogenase (G6PD) deficiency D55.0] | 3.0 – 7.0 uIU/mL (D55.0) | Clinical Reference Target Range |
Marcus Sterling (AI Healthcare Price Auditor) & Dr. Vance
Check Drug Interactions →
FDA-Monographed Medications & Public Cash Price Reference for Glucose-6-phosphate dehydrogenase (G6PD) deficiency
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Acanya (Clindamycin Phosphate and Benzoyl Peroxide) Acanya • RxCUI 885131-B13548132 | Lincosamide Antibacterial | 79% | $0.1517 | $ 39.27 /mo |
| Cleocin Phosphate (Clindamycin Phosphate) Cleocin Phosphate • RxCUI 1737244 | Lincosamide Antibacterial | 90% | $0.1517 | $ 19.42 /mo |
| Clindamycin Phosphate Topical Solution USP, 1% Clindamycin Phoaphate Topical Solution USP, 1% • RxCUI RXN-21922002-2309 | Lincosamide Antibacterial | 89% | $0.1487 | $ 14.52 /mo |
| Butalbital, Aspirin, Caffeine and Codeine Phosphate Ascomp with Codeine • RxCUI RXN-636292952-2686 | Barbiturate | 87% | $0.9392 | $ 46.54 /mo |
| Clindamycin Clindagel, Cleocin • RxCUI 309332 | Lincosamide Antibacterial | 75% | $0.1517 | $ 7.36 /mo |
| Clindamycin Phosphate and Benzoyl Peroxide (Clindamycin and Benzoyl Peroxide Gel) Clindamycin Phosphate and Benzoyl Peroxide • RxCUI 309333 | Lincosamide Antibacterial | 83% | $0.4647 | $ 41.96 /mo |
| Promethazine Hydrochloride and Codeine Phosphate Promethazine Hydrochloride and Codeine Phosphate Generic • RxCUI 991486 | Opioid Agonist | 85% | $0.0505 | $ 10.54 /mo |
| Sivextro (Tedizolid Phosphate) Sivextro • RxCUI RXN-B67919040 | Oxazolidinone Antibacterial | 83% | $445.4998 | $ 640.00 /mo |
| Clindamycin Phosphate Topical USP, 1% Clindamycin Phoaphate Topical USP, 1% • RxCUI RXN-500906592-2855 | Lincosamide Antibacterial | 92% | $0.1517 | $ 14.64 /mo |
| Ivosidenib Tibsovo • RxCUI RXN-72694617-2911 | Isocitrate Dehydrogenase 1 Inhibitor | 84% | $1.4500 | $ 67.22 /mo |
| Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Generic • RxCUI RXN-43386030-1792 | Osmotic Laxative | 79% | $1.1000 | $ 53.05 /mo |
| Anticoagulant Citrate Phosphate Dextrose Solution Sterile Cord Blood Collection Unit (Msc127d), Sterile Cord Blood Collection Unit (Msc128d) • RxCUI RXN-14498003-2121 | Calculi Dissolution Agent | 85% | $1.3400 | $ 62.77 /mo |
| Chloroquine Phosphate Aralen • RxCUI 1116758 | Antimalarial | 75% | $5.7554 | $ 56.75 /mo |
| Oseltamivir Phosphate (Oseltamivir Acid) Oseltamivir Phosphate • RxCUI RXN-B707711598 | Neuraminidase Inhibitor | 80% | $0.1700 | $ 20.74 /mo |
| Idhifa (Enasidenib Mesylate) Idhifa • RxCUI RXN-B59572710 | Isocitrate Dehydrogenase 2 Inhibitor | 77% | $3.2500 | $ 242.50 /mo |
| Acetaminophen and Codeine Acetaminophen and Codeine Generic • RxCUI 993781 | Opioid Agonist | 94% | $0.2090 | $ 16.97 /mo |
Dr. Lin (AI PubMed Clinical Trial Lead)
Browse All PubMed Translations →
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Glucose-6-phosphate dehydrogenase (G6PD) deficiency)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of 11 sodium-glucose cotransporter-2 inhibitors at different: What a 9,144-Participant Study Found As add-on therapy, SGLT2is demonstrated favourable antidiabetic efficacy and acceptable safety. BMJ open • 2025-02-26 • Meta-Analysis | N = 9,144 | 99/100 | PMID 40010842 ↗ |
| New Insights on Glucose levels predict hospitalization for congestive heart failure in patients: What a 25,620-Participant Study Found Fasting plasma glucose is an independent predictor of hospitalization for CHF in high-risk subjects. Circulation • 2007-03-20 • Randomized Controlled Trial | N = 25,620 | 96/100 | PMID 17339550 ↗ |
| Can This Approach Help? Inside the Latest Research on Continuous Glucose Monitoring in Non–Insulin-Treated Type 2 New England Journal of Medicine, Volume 395, Issue 17 , Page 1717-1727, October 29, 2026. New England Journal of Medicine • 2026-10-14 • Peer-Reviewed Journal (Clinical Trials) | Multi-cohort | 95/100 | PMID NEJM-1332772225 ↗ |
| Check Your Medicine Cabinet: Hospital Glucose Meter Correction: Nova Biomedical Updates Use Instructions for StatStri Update use instructions for StatStrip Glucose Hospital Meter Systems due to the potential for glucose results to be assigned to the incorrect patient. FDA MedWatch Safety Alerts • 2026-10-30 • FDA Safety Alert | Multi-cohort | 95/100 | PMID FDA_MEDWATCH-1688403489 ↗ |
| New Insights on Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in: What a 4,300-Participant Study Found Despite similar glycemic efficacy in a relatively short term, SGLT2 inhibitors are more effective in the longer term than SUs as add-on to metformin. Clinical drug investigation • 2019-06-15 • Meta-Analysis | N = 4,300 | 94/100 | PMID 31041606 ↗ |
Zero-PHI Patient Support & Cohort Discussions
Glucose-6-phosphate dehydrogenase (G6PD) deficiency Patient Community & “People Like Me” Threads
“People Like Me” Cohort Filter (Zero-PHI)
Filter Glucose-6-phosphate dehydrogenase (G6PD) deficiency community threads and patient logs by age, biological sex, dosage, and treatment duration.
No threads match this cohort filter yet. Click + Start Anonymous Discussion to ask the community about Glucose-6-phosphate dehydrogenase (G6PD) deficiency.